A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer

被引：11

作者：

Antman, KH ^{[1
]}

机构：

[1] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2001年 / 37卷 / 02期

关键词：

breast cancer; high-dose chemotherapy; blood and marrow transplantation; randomised trials; metastatic; high risk;

D O I：

10.1016/S0959-8049(00)00347-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Data from 11 randomised studies on high-dose chemotherapy for breast cancer are currently available. Most investigators, patients and insurers would agree that the two discredited South African trials are uninterpretable, and that the Scandinavian trial (which compares one very high-dose cycle versus six escalated dose cycles) does not ask the question of high-dose therapy versus conventional-dose therapy. Only two of the eight remaining studies randomised more than 200 patients (783 patients for the Cancer and Leukaemia Group B (CALGB) and 885 for the Dutch study). Both of these studies have trends in relapse-free survival favouring high-dose therapy. In a planned analysis of the first 284 patients entered into the Dutch study, with a median follow-up approximately 7 years, both disease-free and overall survival were significantly improved in the high-dose therapy arm. These and the other trials are discussed in detail below. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：173 / 179

页数：7

共 31 条

[1]

BERGH J, 1999, P AN M AM SOC CLIN, V18, pA2

[2] RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].

BEZWODA, WR ;

SEYMOUR, L ;

DANSEY, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2483-2489

[3]

BEZWODA WR, 1999, P AN M AM SOC CLIN, V18, pA2

[4]

BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, pA115

[5] TREATMENT OF ESTROGEN RECEPTOR-NEGATIVE OR HORMONALLY REFRACTORY BREAST-CANCER WITH DOUBLE HIGH-DOSE CHEMOTHERAPY INTENSIFICATION AND BONE-MARROW SUPPORT [J].

DUNPHY, FR ;

SPITZER, G ;

BUZDAR, AU ;

HORTOBAGYI, GN ;

HORWITZ, LJ ;

YAU, JC ;

SPINOLO, JA ;

JAGANNATH, S ;

HOLMES, F ;

WALLERSTEIN, RO ;

BOHANNAN, PA ;

DICKE, KA .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1207-1216

[6] Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25 [J].

Fisher, B ;

Anderson, S ;

DeCillis, A ;

Dimitrov, N ;

Atkins, JN ;

Fehrenbacher, L ;

Henry, PH ;

Romond, EH ;

Lanier, KS ;

Davila, E ;

Kardinal, CG ;

Laufman, L ;

Pierce, HI ;

Abramson, N ;

Keller, AM ;

Hamm, JT ;

Wickerham, DL ;

Begovic, M ;

Tan-Chiu, E ;

Tian, W ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3374-3388

[7] Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer [J].

Greenberg, PAC ;

Hortobagyi, GN ;

Smith, TL ;

Ziegler, LD ;

Frye, DK ;

Buzdar, AU .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2197-2205

[8] EFFECTS OF TAXOTERE AND TAXOL ON INVITRO COLONY FORMATION OF FRESHLY EXPLANTED HUMAN TUMOR-CELLS [J].

HANAUSKE, AR ;

DEGEN, D ;

HILSENBECK, SG ;

BISSERY, MC ;

VONHOFF, DD .

ANTI-CANCER DRUGS, 1992, 3 (02) :121-124

[9]

HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, pA101

[10] Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma [J].

Hortobagyi, GN ;

Buzdar, AU ;

Theriault, RL ;

Valero, V ;

Frye, D ;

Booser, DJ ;

Holmes, FA ;

Giralt, S ;

Khouri, I ;

Andersson, B ;

Gajewski, JL ;

Rondon, G ;

Smith, TL ;

Singletary, SE ;

Ames, FC ;

Sneige, N ;

Strom, EA ;

McNeese, MD ;

Deisseroth, AB ;

Champlin, RE .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (03) :225-233

← 1 2 3 4 →